Roche (RHHBY) believes that while its agreement with the U.S. government will keep its medicines exempt from the current round of import tariffs, its diagnostics division remains exposed and may face renewed duties after an initial 150-day period, Reuters reports, citing statement made by Chairman Severin Schwan.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Genentech publishes ALLEGORY trial data in the New England Journal of Medicine
- Genentech reports Phase 2 ZUPREME-1 weight loss trial met primary endpoint
- Roche: Fenebrutinib Safety Concerns Skew Risk‑Reward, Driving Sell Rating
- Genentech announces fenebrutinib study met primary endpoint
- Roche genome pricing positive for Illumina, says TD Cowen